Day 2 at JP Morgan ’18: Pharma’s need for more diversity and data sharing grab the spotlight
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday’s events.
A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday’s events.
How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.
A sea change may be afoot in OTC, with multiple healthcare businesses in play. Could consumer goods companies fill the void left by big pharma?
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has “a great story to tell, with or without the data.”
Emmy-nominated Maia Samuel becomes executive director of expanded Haymarket Content Lab; Bernadette Casey promoted to executive director of Haymarket Content Hub.
Trade group PhRMA’s CEO talks about his first year in the job amid public outrage about price gouging.
The communications team, led by Jeff Winton, is again researching Astellas’ reputation for an updated picture on where the campaign has gotten them so far.
Management turnover has brought the opportunity to keep up the pressure.
They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry’s drug-pricing practices.
Merck CEO Kenneth Frazier’s exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
Please login or register first to view this content.